Seymour JF - Search Results

1

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.

Blombery P, Thompson ER, Lew TE, Tiong IS, Bennett R, Cheah CY, Lewis KL, Handunnetti SM, Tang CPS, Roberts A, Seymour JF, Tam CS. Blombery P, et al. Among authors: seymour jf. Blood Adv. 2022 Oct 25;6(20):5589-5592. doi: 10.1182/bloodadvances.2022008325. Blood Adv. 2022. PMID: 35901282 Free PMC article.

2

Mini-allografts' for haematological malignancies: an alternative to conventional myeloablative marrow transplantation.

Grigg A, Seymour JF, Roberts A, Szer J. Grigg A, et al. Among authors: seymour jf. Aust N Z J Med. 1999 Jun;29(3):308-14. doi: 10.1111/j.1445-5994.1999.tb00711.x. Aust N Z J Med. 1999. PMID: 10868492

3

Acute left ventricular failure following melphalan and fludarabine conditioning.

Ritchie DS, Seymour JF, Roberts AW, Szer J, Grigg AP. Ritchie DS, et al. Among authors: seymour jf. Bone Marrow Transplant. 2001 Jul;28(1):101-3. doi: 10.1038/sj.bmt.1703098. Bone Marrow Transplant. 2001. PMID: 11498753

4

Diffuse large B-cell non-Hodgkin's lymphoma presenting as Sister Joseph's nodule.

Tam C, Turner H, Hicks RJ, Seymour JF. Tam C, et al. Among authors: seymour jf. Leuk Lymphoma. 2002 Oct;43(10):2055-7. doi: 10.1080/1042819021000016005. Leuk Lymphoma. 2002. PMID: 12481909 Review.

5

Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.

Tam CS, Wolf MM, Januszewicz EH, Prince HM, Westerman D, Seymour JF. Tam CS, et al. Among authors: seymour jf. Cancer. 2004 May 15;100(10):2181-9. doi: 10.1002/cncr.20234. Cancer. 2004. PMID: 15139062 Free article. Review.

6

Leukaemic subtype of marginal zone lymphoma: a presentation of three cases and literature review.

Tam CS, Prince HM, Westerman D, Seymour JF, Juneja S. Tam CS, et al. Among authors: seymour jf. Leuk Lymphoma. 2004 Apr;45(4):705-10. doi: 10.1080/10428190310001615657. Leuk Lymphoma. 2004. PMID: 15160943 Review.

7

Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies.

Tam CS, Galanos J, Seymour JF, Pitman AG, Stark RJ, Prince HM. Tam CS, et al. Among authors: seymour jf. Am J Hematol. 2004 Sep;77(1):72-6. doi: 10.1002/ajh.20147. Am J Hematol. 2004. PMID: 15307110 Free article.

8

A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies.

Tam CS, Wolf MM, Januszewicz EH, Grigg AP, Prince HM, Westerman D, Seymour JF. Tam CS, et al. Among authors: seymour jf. Cancer. 2004 Nov 1;101(9):2042-9. doi: 10.1002/cncr.20615. Cancer. 2004. PMID: 15372472 Free article.

9

Ante-mortem diagnosis of localized invasive esophageal aspergillosis in a patient with acute myeloid leukemia.

Chionh F, Herbert KE, Seymour JF, Prince HM, Wolf M, Zimet A, Tam C, Kennedy GA. Chionh F, et al. Among authors: seymour jf. Leuk Lymphoma. 2005 Apr;46(4):603-5. doi: 10.1080/10428190400025138. Leuk Lymphoma. 2005. PMID: 16019490

10

A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.

Prince HM, Mileshkin L, Roberts A, Ganju V, Underhill C, Catalano J, Bell R, Seymour JF, Westerman D, Simmons PJ, Lillie K, Milner AD, Iulio JD, Zeldis JB, Ramsay R. Prince HM, et al. Among authors: seymour jf. Clin Cancer Res. 2005 Aug 1;11(15):5504-14. doi: 10.1158/1078-0432.CCR-05-0213. Clin Cancer Res. 2005. PMID: 16061867 Clinical Trial.

11

Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.

Tam CS, Wolf MM, Westerman D, Januszewicz EH, Prince HM, Seymour JF. Tam CS, et al. Among authors: seymour jf. Clin Lymphoma Myeloma. 2005 Sep;6(2):136-9. doi: 10.3816/CLM.2005.n.040. Clin Lymphoma Myeloma. 2005. PMID: 16231852

12

The infectious consequences of rituximab addition to fludarabine-containing regimens.

Tam CS, Seymour JF. Tam CS, et al. Among authors: seymour jf. Blood. 2006 Apr 1;107(7):3013-4. doi: 10.1182/blood-2005-10-4012. Blood. 2006. PMID: 16554491 Free article. No abstract available.

13

Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.

Tam CS, Wolf M, Prince HM, Januszewicz EH, Westerman D, Lin KI, Carney D, Seymour JF. Tam CS, et al. Among authors: seymour jf. Cancer. 2006 Jun 1;106(11):2412-20. doi: 10.1002/cncr.21882. Cancer. 2006. PMID: 16649223 Free article.

14

The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.

Polizzotto MN, Tam CS, Milner A, Januszewicz EH, Prince HM, Westerman D, Wolf MM, Seymour JF. Polizzotto MN, et al. Among authors: seymour jf. Cancer. 2006 Aug 15;107(4):773-80. doi: 10.1002/cncr.22022. Cancer. 2006. PMID: 16847886 Free article.

15

Treatment-related myelodysplasia following fludarabine combination chemotherapy.

Tam CS, Seymour JF, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Westerman D. Tam CS, et al. Among authors: seymour jf. Haematologica. 2006 Nov;91(11):1546-50. Haematologica. 2006. PMID: 17082012

16

The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.

Ritchie DS, Seymour JF, Grigg AP, Roberts AW, Hoyt R, Thompson S, Szer J, Prince HM. Ritchie DS, et al. Among authors: seymour jf. Ann Hematol. 2007 Feb;86(2):101-5. doi: 10.1007/s00277-006-0193-2. Epub 2006 Nov 7. Ann Hematol. 2007. PMID: 17089127 Clinical Trial.

17

Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib.

Ritchie DS, McBean M, Westerman DA, Kovalenko S, Seymour JF, Dobrovic A. Ritchie DS, et al. Among authors: seymour jf. Blood. 2008 Mar 1;111(5):2896-8. doi: 10.1182/blood-2007-08-107508. Epub 2007 Dec 11. Blood. 2008. PMID: 18073350 Free article.

18

The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.

Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD, Grigg AP, Seymour JF, Szer J, Huang DC, Roberts AW. Mason KD, et al. Among authors: seymour jf. Leukemia. 2009 Nov;23(11):2034-41. doi: 10.1038/leu.2009.151. Epub 2009 Jul 30. Leukemia. 2009. PMID: 19641525

19

Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.

Dickinson M, Hoyt R, Roberts AW, Grigg A, Seymour JF, Prince HM, Szer J, Ritchie D. Dickinson M, et al. Among authors: seymour jf. Br J Haematol. 2010 Jul;150(1):39-45. doi: 10.1111/j.1365-2141.2010.08162.x. Epub 2010 May 7. Br J Haematol. 2010. PMID: 20507301 Free article. Review.

20

Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge.

Thompson PA, Tam CS, Thursky K, Seymour JF. Thompson PA, et al. Among authors: seymour jf. Leuk Lymphoma. 2010 Sep;51(9):1592-5. doi: 10.3109/10428194.2010.509456. Leuk Lymphoma. 2010. PMID: 20807092 No abstract available.

21

Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.

Peinert S, Tam CS, Prince HM, Scarlett J, Wolf MM, Januszewicz EH, Westerman D, Seymour JF. Peinert S, et al. Among authors: seymour jf. Leuk Lymphoma. 2010 Dec;51(12):2188-97. doi: 10.3109/10428194.2010.524326. Epub 2010 Oct 12. Leuk Lymphoma. 2010. PMID: 20939696

22

Carney DA, Westerman DA, Tam CS, Milner A, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Ritchie D, Came N, Seymour JF. Carney DA, et al. Among authors: seymour jf. Leukemia. 2010 Dec;24(12):2056-62. doi: 10.1038/leu.2010.218. Epub 2010 Oct 21. Leukemia. 2010. PMID: 20962860

23

Fludarabine, cyclophosphamide, and rituximab chemotherapy followed by rituximab maintenance in follicular lymphoma: high efficacy may come at a cost?

Tam CS, Seymour JF. Tam CS, et al. Among authors: seymour jf. Leuk Lymphoma. 2011 May;52(5):729-31. doi: 10.3109/10428194.2011.575491. Leuk Lymphoma. 2011. PMID: 21504295 No abstract available.

24

ABVD versus BEACOPP for Hodgkin's lymphoma.

Tam CS, Herschtal A, Seymour JF. Tam CS, et al. Among authors: seymour jf. N Engl J Med. 2011 Oct 20;365(16):1544-5; author reply 1546. doi: 10.1056/NEJMc1109618. N Engl J Med. 2011. PMID: 22010926 No abstract available.

25

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R. Roberts AW, et al. Among authors: seymour jf. J Clin Oncol. 2012 Feb 10;30(5):488-96. doi: 10.1200/JCO.2011.34.7898. Epub 2011 Dec 19. J Clin Oncol. 2012. PMID: 22184378 Free PMC article. Clinical Trial.

26

Local experience with the novel human anti-CD20 antibody, ofatumumab, as salvage treatment for patients with heavily pretreated chronic lymphocytic leukaemia.

Cheah CY, Carney DA, Lim SM, Januszewicz H, Scarlett J, Seymour JF. Cheah CY, et al. Among authors: seymour jf. Intern Med J. 2012 Jul;42(7):846-8. doi: 10.1111/j.1445-5994.2012.02827.x. Intern Med J. 2012. PMID: 22805693 No abstract available.

27

Refining the predictors of risk for central nervous system involvement in patients with mantle cell lymphoma.

Cheah CY, Seymour JF. Cheah CY, et al. Among authors: seymour jf. Leuk Lymphoma. 2013 Sep;54(9):1859-61. doi: 10.3109/10428194.2013.777839. Epub 2013 Apr 2. Leuk Lymphoma. 2013. PMID: 23432685 No abstract available.

28

High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?

George A, Tam CS, Seymour JF. George A, et al. Among authors: seymour jf. Leuk Lymphoma. 2013 Dec;54(12):2575-6. doi: 10.3109/10428194.2013.796059. Epub 2013 May 21. Leuk Lymphoma. 2013. PMID: 23597141 No abstract available.

29

Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.

Cheah CY, George A, Giné E, Chiappella A, Kluin-Nelemans HC, Jurczak W, Krawczyk K, Mocikova H, Klener P, Salek D, Walewski J, Szymczyk M, Smolej L, Auer RL, Ritchie DS, Arcaini L, Williams ME, Dreyling M, Seymour JF; European Mantle Cell Lymphoma Network. Cheah CY, et al. Among authors: seymour jf. Ann Oncol. 2013 Aug;24(8):2119-23. doi: 10.1093/annonc/mdt139. Epub 2013 Apr 24. Ann Oncol. 2013. PMID: 23616279 Free article.

30

All is not lost--the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab.

Cheah CY, Lew TE, Lee R, Tam CS, Seymour JF, Carney DA. Cheah CY, et al. Among authors: seymour jf. Eur J Haematol. 2013 Aug;91(2):189-90. doi: 10.1111/ejh.12138. Epub 2013 Jun 28. Eur J Haematol. 2013. PMID: 23668259 No abstract available.

31

Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.

Haeusler GM, Slavin MA, Seymour JF, Lingaratnam S, Teh BW, Tam CS, Thursky KA, Worth LJ. Haeusler GM, et al. Among authors: seymour jf. Eur J Haematol. 2013 Aug;91(2):157-63. doi: 10.1111/ejh.12135. Epub 2013 Jun 15. Eur J Haematol. 2013. PMID: 23668894 Free PMC article.

32

Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy.

Cheah CY, Hofman MS, Dickinson M, Wirth A, Westerman D, Harrison SJ, Burbury K, Wolf M, Januszewicz H, Herbert K, Prince HM, Carney DA, Ritchie DS, Hicks RJ, Seymour JF. Cheah CY, et al. Among authors: seymour jf. Br J Cancer. 2013 Jul 23;109(2):312-7. doi: 10.1038/bjc.2013.338. Epub 2013 Jun 27. Br J Cancer. 2013. PMID: 23807169 Free PMC article.

33

Rasburicase causing severe oxidative hemolysis and methemoglobinemia in a patient with previously unrecognized glucose-6-phosphate dehydrogenase deficiency.

Cheah CY, Lew TE, Seymour JF, Burbury K. Cheah CY, et al. Among authors: seymour jf. Acta Haematol. 2013;130(4):254-9. doi: 10.1159/000351048. Epub 2013 Jul 11. Acta Haematol. 2013. PMID: 23860572 Free article.

34

Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?

Cheah CY, Seymour JF. Cheah CY, et al. Among authors: seymour jf. Leuk Lymphoma. 2014 Mar;55(3):471-3. doi: 10.3109/10428194.2013.830306. Epub 2013 Nov 14. Leuk Lymphoma. 2014. PMID: 23906017 No abstract available.

35

Chemotherapy versus autologous stem-cell transplantation for the treatment of transformed follicular lymphoma in the rituximab era.

Tam CS, Herschtal A, Dickinson M, George A, Seymour JF. Tam CS, et al. Among authors: seymour jf. J Clin Oncol. 2013 Sep 1;31(25):3166-7. doi: 10.1200/JCO.2013.50.2245. Epub 2013 Aug 5. J Clin Oncol. 2013. PMID: 23918946 No abstract available.

36

Rituximab for the treatment of follicular lymphoma.

Cheah CY, Lingaratnam S, Seymour JF. Cheah CY, et al. Among authors: seymour jf. Future Oncol. 2013 Sep;9(9):1283-98. doi: 10.2217/fon.13.134. Future Oncol. 2013. PMID: 23980675

37

De novo B-cell prolymphocytic leukemia with central nervous system involvement.

Tatarczuch M, Blombery P, Seymour JF. Tatarczuch M, et al. Among authors: seymour jf. Leuk Lymphoma. 2014 Jul;55(7):1665-7. doi: 10.3109/10428194.2013.842991. Epub 2014 Apr 29. Leuk Lymphoma. 2014. PMID: 24047478 No abstract available.

38

Primary testicular lymphoma.

Cheah CY, Wirth A, Seymour JF. Cheah CY, et al. Among authors: seymour jf. Blood. 2014 Jan 23;123(4):486-93. doi: 10.1182/blood-2013-10-530659. Epub 2013 Nov 26. Blood. 2014. PMID: 24282217 Free article. Review.

39

Adding weight to a sinking ship: more reasons not to perform routine surveillance imaging in patients with diffuse large B-cell lymphoma in remission.

Cheah CY, Seymour JF. Cheah CY, et al. Among authors: seymour jf. Leuk Lymphoma. 2014 Oct;55(10):2223-5. doi: 10.3109/10428194.2014.881483. Leuk Lymphoma. 2014. PMID: 24410590 No abstract available.

40

Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy.

Cheah CY, Dickinson M, Hofman MS, George A, Ritchie DS, Prince HM, Westerman D, Harrison SJ, Burbury K, Wolf M, Januszewicz H, Herbert KE, Carney DA, Tam C, Seymour JF. Cheah CY, et al. Among authors: seymour jf. Ann Hematol. 2014 Jul;93(7):1193-200. doi: 10.1007/s00277-014-2040-1. Epub 2014 Mar 5. Ann Hematol. 2014. PMID: 24595733

41

Bone marrow biopsy for the initial staging of patients with lymphoma: too soon to toss the trephine.

Cheah CY, Seymour JF. Cheah CY, et al. Among authors: seymour jf. Oncology (Williston Park). 2013 Dec;27(12):1288, 1290. Oncology (Williston Park). 2013. PMID: 24624548 Free article. No abstract available.

42

The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.

Fleming S, Harrison SJ, Blombery P, Joyce T, Stokes K, Seymour JF, Prince HM, Ritchie D. Fleming S, et al. Among authors: seymour jf. Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):291-6. doi: 10.1016/j.clml.2014.02.001. Epub 2014 Feb 15. Clin Lymphoma Myeloma Leuk. 2014. PMID: 24629850

43

Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.

Cheah CY, Burbury K, Apperley JF, Huguet F, Pitini V, Gardembas M, Ross DM, Forrest D, Genet P, Rousselot P, Patton N, Smith G, Dunbar CE, Ito S, Aguiar RC, Odenike O, Gimelfarb A, Cross NC, Seymour JF. Cheah CY, et al. Among authors: seymour jf. Blood. 2014 Jun 5;123(23):3574-7. doi: 10.1182/blood-2014-02-555607. Epub 2014 Mar 31. Blood. 2014. PMID: 24687085 Free PMC article.

44

The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review.

Cheah CY, Hofman MS, Seymour JF, Ritchie DS, Dickinson M, Wirth A, Prince HM, Wolf M, Januszcewicz EH, Carney DA, Herbert KE, Harrison SJ, Burbury KL, Tam CS. Cheah CY, et al. Among authors: seymour jf. Leuk Lymphoma. 2015 Jan;56(1):49-56. doi: 10.3109/10428194.2014.910656. Epub 2014 Jun 16. Leuk Lymphoma. 2015. PMID: 24724780

45

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.

Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Donaldson Z, Leong M, Fletcher L, Seymour JF, Grigg AP, Ross DM, Hughes TP. Branford S, et al. Among authors: seymour jf. Blood. 2014 Jul 24;124(4):511-8. doi: 10.1182/blood-2014-03-566323. Epub 2014 May 23. Blood. 2014. PMID: 24859364 Free article. Clinical Trial.

46

Primary breast lymphoma.

Cheah CY, Campbell BA, Seymour JF. Cheah CY, et al. Among authors: seymour jf. Cancer Treat Rev. 2014 Sep;40(8):900-8. doi: 10.1016/j.ctrv.2014.05.010. Epub 2014 Jun 6. Cancer Treat Rev. 2014. PMID: 24953564 Review.

47

A new prognostic score for CLL.

Tam CS, Seymour JF. Tam CS, et al. Among authors: seymour jf. Blood. 2014 Jul 3;124(1):1-2. doi: 10.1182/blood-2014-05-575407. Blood. 2014. PMID: 24993873 Free article.

48

A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.

Cheah CY, Herbert KE, O'Rourke K, Kennedy GA, George A, Fedele PL, Gilbertson M, Tan SY, Ritchie DS, Opat SS, Prince HM, Dickinson M, Burbury K, Wolf M, Januszewicz EH, Tam CS, Westerman DA, Carney DA, Harrison SJ, Seymour JF. Cheah CY, et al. Among authors: seymour jf. Br J Cancer. 2014 Sep 9;111(6):1072-9. doi: 10.1038/bjc.2014.405. Epub 2014 Jul 29. Br J Cancer. 2014. PMID: 25072255 Free PMC article.

49

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.

Seymour JF, Kim DW, Rubin E, Haregewoin A, Clark J, Watson P, Hughes T, Dufva I, Jimenez JL, Mahon FX, Rousselot P, Cortes J, Martinelli G, Papayannidis C, Nagler A, Giles FJ. Seymour JF, et al. Blood Cancer J. 2014 Aug 15;4(8):e238. doi: 10.1038/bcj.2014.60. Blood Cancer J. 2014. PMID: 25127392 Free PMC article. Clinical Trial.

50

How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?

Shah N, Tam C, Seymour JF, Rule S. Shah N, et al. Among authors: seymour jf. Leuk Lymphoma. 2015 Jun;56(6):1599-610. doi: 10.3109/10428194.2014.963083. Epub 2014 Nov 20. Leuk Lymphoma. 2015. PMID: 25213181 Review.

51

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. McMullen JR, et al. Among authors: seymour jf. Blood. 2014 Dec 11;124(25):3829-30. doi: 10.1182/blood-2014-10-604272. Blood. 2014. PMID: 25498454 Free article. No abstract available.

52

Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang ML. Cheah CY, et al. Among authors: seymour jf. Ann Oncol. 2015 Jun;26(6):1175-1179. doi: 10.1093/annonc/mdv111. Epub 2015 Feb 23. Ann Oncol. 2015. PMID: 25712454 Free article.

53

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

Komrokji RS, Seymour JF, Roberts AW, Wadleigh M, To LB, Scherber R, Turba E, Dorr A, Zhu J, Wang L, Granston T, Campbell MS, Mesa RA. Komrokji RS, et al. Among authors: seymour jf. Blood. 2015 Apr 23;125(17):2649-55. doi: 10.1182/blood-2013-02-484832. Epub 2015 Mar 11. Blood. 2015. PMID: 25762180 Free PMC article. Clinical Trial.

54

Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?

Cheah CY, Seymour JF. Cheah CY, et al. Among authors: seymour jf. Curr Oncol Rep. 2015 Jun;17(6):25. doi: 10.1007/s11912-015-0450-4. Curr Oncol Rep. 2015. PMID: 25912004 Review.

55

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.

Roberts AW, Advani RH, Kahl BS, Persky D, Sweetenham JW, Carney DA, Yang J, Busman TB, Enschede SH, Humerickhouse RA, Seymour JF. Roberts AW, et al. Among authors: seymour jf. Br J Haematol. 2015 Sep;170(5):669-78. doi: 10.1111/bjh.13487. Epub 2015 May 5. Br J Haematol. 2015. PMID: 25942994 Free PMC article. Clinical Trial.

56

The molecular pathogenesis of B-cell non-Hodgkin lymphoma.

Blombery PA, Wall M, Seymour JF. Blombery PA, et al. Among authors: seymour jf. Eur J Haematol. 2015 Oct;95(4):280-93. doi: 10.1111/ejh.12589. Epub 2015 Jun 9. Eur J Haematol. 2015. PMID: 25996166 Review.

57

Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy.

Lew TE, Cheah CY, Carney DA, Prince HM, Wolf M, Bazargan A, Januszewicz EH, Filshie R, Westerman D, Seymour JF, Tam CS. Lew TE, et al. Among authors: seymour jf. Leuk Lymphoma. 2016 May;57(5):1044-53. doi: 10.3109/10428194.2015.1096353. Epub 2015 Nov 20. Leuk Lymphoma. 2016. PMID: 26464106

58

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner CM, Döhner H, Stilgenbauer S, Hallek M. Fischer K, et al. Among authors: seymour jf. Blood. 2016 Jan 14;127(2):208-15. doi: 10.1182/blood-2015-06-651125. Epub 2015 Oct 20. Blood. 2016. PMID: 26486789 Free article. Clinical Trial.

59

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF. Roberts AW, et al. Among authors: seymour jf. N Engl J Med. 2016 Jan 28;374(4):311-22. doi: 10.1056/NEJMoa1513257. Epub 2015 Dec 6. N Engl J Med. 2016. PMID: 26639348 Free PMC article. Clinical Trial.

60

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.

Cheah CY, Belada D, Fanale MA, Janikova A, Czucman MS, Flinn IW, Kapp AV, Ashkenazi A, Kelley S, Bray GL, Holden S, Seymour JF. Cheah CY, et al. Among authors: seymour jf. Lancet Haematol. 2015 Apr;2(4):e166-74. doi: 10.1016/S2352-3026(15)00026-5. Epub 2015 Mar 25. Lancet Haematol. 2015. PMID: 26687959 Clinical Trial.

61

Mantle Cell Lymphoma.

Cheah CY, Seymour JF, Wang ML. Cheah CY, et al. Among authors: seymour jf. J Clin Oncol. 2016 Apr 10;34(11):1256-69. doi: 10.1200/JCO.2015.63.5904. Epub 2016 Jan 11. J Clin Oncol. 2016. PMID: 26755518 Review.

62

Disseminated visceral varicella zoster virus presenting with the constellation of colonic pseudo-obstruction, acalculous cholecystitis and syndrome of inappropriate ADH secretion.

Braude MR, Trubiano JA, Heriot A, Dickinson M, Carney D, Seymour JF, Tam CS. Braude MR, et al. Among authors: seymour jf. Intern Med J. 2016 Feb;46(2):238-9. doi: 10.1111/imj.12977. Intern Med J. 2016. PMID: 26899893 No abstract available.

63

Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia.

Tam CS, Kimber T, Seymour JF. Tam CS, et al. Among authors: seymour jf. Br J Haematol. 2017 Mar;176(5):829-831. doi: 10.1111/bjh.14000. Epub 2016 Feb 25. Br J Haematol. 2017. PMID: 26915463 Free article. No abstract available.

64

Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.

Tam CS, Seymour JF, Roberts AW. Tam CS, et al. Among authors: seymour jf. Semin Oncol. 2016 Apr;43(2):274-9. doi: 10.1053/j.seminoncol.2016.02.014. Epub 2016 Feb 6. Semin Oncol. 2016. PMID: 27040706 Review.

65

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, Yu L, Brown JR, Westerman D, Si EG, Majewski IJ, Segal D, Heitner Enschede SL, Huang DC, Davids MS, Letai A, Roberts AW. Anderson MA, et al. Among authors: seymour jf. Blood. 2016 Jun 23;127(25):3215-24. doi: 10.1182/blood-2016-01-688796. Epub 2016 Apr 11. Blood. 2016. PMID: 27069256 Free PMC article.

66

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. Stilgenbauer S, et al. Among authors: seymour jf. Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10. Lancet Oncol. 2016. PMID: 27178240 Clinical Trial.

67

Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors.

Chan KL, Blombery P, Jones K, Lade S, Carney D, Tran H, Seymour JF, Tam CS. Chan KL, et al. Among authors: seymour jf. Br J Haematol. 2017 Apr;177(2):324-328. doi: 10.1111/bjh.14062. Epub 2016 May 15. Br J Haematol. 2017. PMID: 27196127 Free article. No abstract available.

68

New Agents to Treat Chronic Lymphocytic Leukemia.

Roberts AW, Davids MS, Seymour JF. Roberts AW, et al. Among authors: seymour jf. N Engl J Med. 2016 Jun 2;374(22):2186-7. doi: 10.1056/NEJMc1602674. N Engl J Med. 2016. PMID: 27248631 Free article. No abstract available.

69

High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma.

Cheah CY, Joske D, Cull G, Gilbertson M, Opat SS, Tam CS, Wirth A, Seymour JF. Cheah CY, et al. Among authors: seymour jf. Br J Haematol. 2017 Sep;178(6):991-994. doi: 10.1111/bjh.14187. Epub 2016 Jul 29. Br J Haematol. 2017. PMID: 27470657 Free article. No abstract available.

70

Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement.

El-Galaly TC, Cheah CY, Hutchings M, Mikhaeel NG, Savage KJ, Sehn LH, Barrington S, Hansen JW, Poulsen MØ, Smith D, Rady K, Mylam KJ, Larsen TS, Holmberg S, Juul MB, Cordua S, Clausen MR, Jensen KB, Bøgsted M, Johnsen HE, Seymour JF, Connors JM, Brown PD, Villa D. El-Galaly TC, et al. Among authors: seymour jf. Br J Haematol. 2016 Dec;175(5):876-883. doi: 10.1111/bjh.14325. Epub 2016 Sep 29. Br J Haematol. 2016. PMID: 27681999 Free article.

71

Transformed Lymphoma.

Anderson MA, Blombery P, Seymour JF. Anderson MA, et al. Among authors: seymour jf. Hematol Oncol Clin North Am. 2016 Dec;30(6):1317-1332. doi: 10.1016/j.hoc.2016.07.012. Hematol Oncol Clin North Am. 2016. PMID: 27888883 Review.

72

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B. Grever MR, et al. Among authors: seymour jf. Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30. Blood. 2017. PMID: 27903528 Free PMC article.

73

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW. Seymour JF, et al. Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13. Lancet Oncol. 2017. PMID: 28089635 Free PMC article. Clinical Trial.

74

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF. Davids MS, et al. Among authors: seymour jf. J Clin Oncol. 2017 Mar 10;35(8):826-833. doi: 10.1200/JCO.2016.70.4320. Epub 2017 Jan 17. J Clin Oncol. 2017. PMID: 28095146 Free PMC article.

75

Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.

Roberts AW, Stilgenbauer S, Seymour JF, Huang DCS. Roberts AW, et al. Among authors: seymour jf. Clin Cancer Res. 2017 Aug 15;23(16):4527-4533. doi: 10.1158/1078-0432.CCR-16-0955. Epub 2017 Jan 18. Clin Cancer Res. 2017. PMID: 28100580 Review.

76

When to treat patients with relapsed follicular lymphoma.

Cheah CY, Seymour JF. Cheah CY, et al. Among authors: seymour jf. Expert Rev Hematol. 2017 Mar;10(3):187-191. doi: 10.1080/17474086.2017.1291339. Epub 2017 Feb 15. Expert Rev Hematol. 2017. PMID: 28164722 Review.

77

The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.

El-Galaly TC, Villa D, Michaelsen TY, Hutchings M, Mikhaeel NG, Savage KJ, Sehn LH, Barrington S, Hansen JW, Smith D, Rady K, Mylam KJ, Larsen TS, Holmberg S, Juul MB, Cordua S, Clausen MR, Jensen KB, Johnsen HE, Seymour JF, Connors JM, de Nully Brown P, Bøgsted M, Cheah CY. El-Galaly TC, et al. Among authors: seymour jf. Eur J Cancer. 2017 Apr;75:195-203. doi: 10.1016/j.ejca.2016.12.029. Epub 2017 Feb 23. Eur J Cancer. 2017. PMID: 28237865 Free article.

78

Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia.

Yeh P, Hunter T, Sinha D, Ftouni S, Wallach E, Jiang D, Chan YC, Wong SQ, Silva MJ, Vedururu R, Doig K, Lam E, Arnau GM, Semple T, Wall M, Zivanovic A, Agarwal R, Petrone P, Jones K, Westerman D, Blombery P, Seymour JF, Papenfuss AT, Dawson MA, Tam CS, Dawson SJ. Yeh P, et al. Among authors: seymour jf. Nat Commun. 2017 Mar 17;8:14756. doi: 10.1038/ncomms14756. Nat Commun. 2017. PMID: 28303898 Free PMC article.

79

Primary Breast Lymphoma-Population-Level Insights into an Infrequent but Increasingly Recognized Subtype of Lymphoma.

Blombery P, Prince HM, Seymour JF. Blombery P, et al. Among authors: seymour jf. J Natl Cancer Inst. 2017 Jun 1;109(6). doi: 10.1093/jnci/djx010. J Natl Cancer Inst. 2017. PMID: 28376146 No abstract available.

80

Choosing and sequencing novel drugs in CLL: dealing with an embarrassment of riches?

Tam CS, Seymour JF. Tam CS, et al. Among authors: seymour jf. Ann Oncol. 2017 May 1;28(5):920-921. doi: 10.1093/annonc/mdx103. Ann Oncol. 2017. PMID: 28379289 Free article. No abstract available.

81

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.

Anderson MA, Tam C, Lew TE, Juneja S, Juneja M, Westerman D, Wall M, Lade S, Gorelik A, Huang DCS, Seymour JF, Roberts AW. Anderson MA, et al. Among authors: seymour jf. Blood. 2017 Jun 22;129(25):3362-3370. doi: 10.1182/blood-2017-01-763003. Epub 2017 May 4. Blood. 2017. PMID: 28473407 Free article. Clinical Trial.

82

Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era.

Butler LA, Tam CS, Seymour JF. Butler LA, et al. Among authors: seymour jf. Blood Rev. 2017 Sep;31(5):318-327. doi: 10.1016/j.blre.2017.05.002. Epub 2017 May 3. Blood Rev. 2017. PMID: 28499646 Review.

83

Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.

Chai KL, Rowan G, Seymour JF, Burbury K, Carney D, Tam CS. Chai KL, et al. Among authors: seymour jf. Leuk Lymphoma. 2017 Dec;58(12):2811-2814. doi: 10.1080/10428194.2017.1315115. Epub 2017 May 15. Leuk Lymphoma. 2017. PMID: 28504030 Review.

84

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma.

El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, Dann EJ, Thompson CA, Inbar T, Maurer MJ, Gade IL, Juul MB, Hansen JW, Holmberg S, Larsen TS, Cordua S, Mikhaeel NG, Hutchings M, Seymour JF, Clausen MR, Smith D, Opat S, Gilbertson M, Thanarajasingam G, Villa D. El-Galaly TC, et al. Among authors: seymour jf. Eur J Cancer. 2018 Apr;93:57-68. doi: 10.1016/j.ejca.2018.01.073. Epub 2018 Feb 21. Eur J Cancer. 2018. PMID: 29477102 Free PMC article.

85

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. Hallek M, et al. Among authors: seymour jf. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. Blood. 2018. PMID: 29540348 Free article.

86

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.

Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW. Tam CS, et al. Among authors: seymour jf. N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519. N Engl J Med. 2018. PMID: 29590547 Free article. Clinical Trial.

87

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG. Stilgenbauer S, et al. Among authors: seymour jf. J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1. J Clin Oncol. 2018. PMID: 29715056 Clinical Trial.

88

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF. Davids MS, et al. Among authors: seymour jf. Clin Cancer Res. 2018 Sep 15;24(18):4371-4379. doi: 10.1158/1078-0432.CCR-17-3761. Epub 2018 Jun 12. Clin Cancer Res. 2018. PMID: 29895707

89

"Reversible" myelodysplastic syndrome or ineffectual clonal haematopoiesis? - add(6p) myeloid neoplasm with a spontaneous cytogenetic remission.

Rady K, Blombery P, Westerman DA, Wall M, Curtis M, Campbell LJ, Seymour JF. Rady K, et al. Among authors: seymour jf. Leuk Res. 2018 Oct;73:1-4. doi: 10.1016/j.leukres.2018.08.010. Epub 2018 Aug 16. Leuk Res. 2018. PMID: 30170269

90

Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies.

Tiong IS, Reynolds J, Bradstock KF, Seymour JF, Wei AH; Australasian Leukaemia & Lymphoma Group. Tiong IS, et al. Among authors: seymour jf. Blood Cancer J. 2018 Aug 22;8(9):84. doi: 10.1038/s41408-018-0121-4. Blood Cancer J. 2018. PMID: 30190488 Free PMC article. No abstract available.

91

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

Davids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, Foss F, Roberts AW, Seymour JF, Humerickhouse RA, Tam CS. Davids MS, et al. Among authors: seymour jf. J Clin Oncol. 2018 Oct 25:JCO1800359. doi: 10.1200/JCO.18.00359. Online ahead of print. J Clin Oncol. 2018. PMID: 30359156 No abstract available.

92

Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.

Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, Thijssen R, Yeh P, Wong SQ, Ftouni S, Lam EYN, Anderson MA, Pott C, Gilan O, Bell CC, Knezevic K, Blombery P, Rayeroux K, Zordan A, Li J, Huang DCS, Wall M, Seymour JF, Gray DHD, Roberts AW, Dawson MA, Dawson SJ. Agarwal R, et al. Among authors: seymour jf. Nat Med. 2019 Jan;25(1):119-129. doi: 10.1038/s41591-018-0243-z. Epub 2018 Nov 19. Nat Med. 2019. PMID: 30455436

93

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, Teh CE, Nguyen T, Xu Z, Flensburg C, Lew TE, Majewski IJ, Gray DHD, Westerman DA, Tam CS, Seymour JF, Czabotar PE, Huang DCS, Roberts AW. Blombery P, et al. Among authors: seymour jf. Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4. Cancer Discov. 2019. PMID: 30514704

94

Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.

Kenealy M, Hertzberg M, Benson W, Taylor K, Cunningham I, Stevenson W, Hiwase D, Eek R, Zantomio D, Jong S, Wall M, Blombery P, Gerber T, Debrincat M, Zannino D, Seymour JF. Kenealy M, et al. Among authors: seymour jf. Haematologica. 2019 Apr;104(4):700-709. doi: 10.3324/haematol.2018.201152. Epub 2018 Dec 13. Haematologica. 2019. PMID: 30545923 Free PMC article. Clinical Trial.

95

A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.

Ng ZY, Bishton M, Ritchie D, Campbell R, Gilbertson M, Hill K, Ratnasingam S, Schwarer A, Manos K, Shorten S, Ng M, Nelson N, Xin L, De Mel Widanalage S, Sunny T, Purtill D, Poon M, Johnston A, Cochrane T, Lee HP, Hapgood G, Tam C, Opat S, Hawkes E, Seymour J, Cheah CY. Ng ZY, et al. Hematol Oncol. 2019 Aug;37(3):253-260. doi: 10.1002/hon.2618. Epub 2019 May 24. Hematol Oncol. 2019. PMID: 30983008

96

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF. Roberts AW, et al. Among authors: seymour jf. Blood. 2019 Jul 11;134(2):111-122. doi: 10.1182/blood.2018882555. Epub 2019 Apr 25. Blood. 2019. PMID: 31023700 Free PMC article. Clinical Trial.

97

Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.

Flinsenberg TWH, Tromedjo CC, Hu N, Liu Y, Guo Y, Thia KYT, Noori T, Song X, Aw Yeang HX, Tantalo DG, Handunnetti S, Seymour JF, Roberts AW, Ritchie D, Koldej R, Neeson PJ, Wang L, Trapani JA, Tam CS, Voskoboinik I. Flinsenberg TWH, et al. Among authors: seymour jf. Haematologica. 2020 Jan 31;105(2):e76-e79. doi: 10.3324/haematol.2019.220590. Print 2020. Haematologica. 2020. PMID: 31171645 Free PMC article. No abstract available.

98

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma.

Blombery P, Birkinshaw RW, Nguyen T, Gong JN, Thompson ER, Xu Z, Westerman DA, Czabotar PE, Dickinson M, Huang DCS, Seymour JF, Roberts AW. Blombery P, et al. Among authors: seymour jf. Br J Haematol. 2019 Sep;186(6):e188-e191. doi: 10.1111/bjh.16069. Epub 2019 Jun 24. Br J Haematol. 2019. PMID: 31234236 Free article. No abstract available.

99

High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia - lessons for immunopathogenesis and prescribing.

Meher-Homji Z, Tam CS, Siderov J, Seymour JF, Holmes NE, Chua KYL, Phillips EJ, Slavin MA, Trubiano JA. Meher-Homji Z, et al. Among authors: seymour jf. Leuk Lymphoma. 2019 Dec;60(14):3455-3460. doi: 10.1080/10428194.2019.1633640. Epub 2019 Jul 1. Leuk Lymphoma. 2019. PMID: 31256738 Free PMC article.

100

Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.

Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Tam CS, et al. Among authors: seymour jf. Blood. 2019 Sep 12;134(11):851-859. doi: 10.1182/blood.2019001160. Epub 2019 Jul 24. Blood. 2019. PMID: 31340982 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

571 results

Search Page

Filters